Hotline:
+ 49 (0) 2204 2918806

Market studies for category Arthritis

Items 1 to 10 of 27 total

  1. 1
  2. | 2
  3. | 3
  1. Net price*
    Year
  2. $4,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update

    GlobalData
    138 pages
    Introduction GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update”. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as:
    Englisch | Report | SKU: 329152
  3. $6,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    Remicade (Rheumatoid Arthritis) Forecast and Market Analysis

    GlobalData
    40 pages
    Introduction GlobalData has released its new PharmaPoint Drug Evaluation report, Remicade (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, taba
    Englisch | Report | SKU: 329157
  4. $4,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis Event-Driven Update

    GlobalData
    127 pages
    Introduction GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis Event-Driven Update”. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lill
    Englisch | Report | SKU: 329162
  5. $6,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis

    GlobalData
    47 pages
    Introduction GlobalData has released its new PharmaPoint Drug Evaluation report, Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF,
    Englisch | Report | SKU: 329168
  6. $6,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis

    GlobalData
    45 pages
    Introduction GlobalData has released its new PharmaPoint Drug Evaluation report, Sirukumab (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tab
    Englisch | Report | SKU: 329177
  7. $4,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update

    GlobalData
    84 pages
    Introduction GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - India Drug Forecast and Market Analysis Event-Driven Update”. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lill
    Englisch | Report | SKU: 329566
  8. $6,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    Humira (Rheumatoid Arthritis) Forecast and Market Analysis

    GlobalData
    36 pages
    Introduction GlobalData has released its new PharmaPoint Drug Evaluation report, Humira (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalu
    Englisch | Report | SKU: 329155
  9. $4,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    PharmaPoint: Rheumatoid Arthritis - Spain Drug Forecast and Market Analysis Event-Driven Update

    GlobalData
    128 pages
    Introduction GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - Spain Drug Forecast and Market Analysis Event-Driven Update”. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lill
    Englisch | Report | SKU: 329160
  10. $4,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis Event-Driven Update

    GlobalData
    123 pages
    Introduction GlobalData has released its new Country report, “PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis Event-Driven Update”. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli
    Englisch | Report | SKU: 329165
  11. $6,995.00
    2012
    Für diese Studie liegt keine Bewertung vor.

    Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis

    GlobalData
    45 pages
    Introduction GlobalData has released its new PharmaPoint Drug Evaluation report, Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, t
    Englisch | Report | SKU: 329173

Items 1 to 10 of 27 total

  1. 1
  2. | 2
  3. | 3